Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity
Blinatumomab combined with low-dose chemotherapy and TKIs demonstrated a trend toward improved MRD negativity, lower relapse rates, and reduced hematologic toxicity compared to conventional chemotherapy. These findings support further investigation in larger trials to confirm clinical benefit.
Authors
- Shujuan Xu
- Qiaoqiao Song (ORCID: https://orcid.org/0000-0003-4532-5055)
- Zhenshu Xu (ORCID: https://orcid.org/0000-0002-4803-3990)
- Ping Weng (ORCID: https://orcid.org/0009-0001-7942-1099)
- Huijian Zheng
- Xinxin Liu
- Zeyuan Yu (ORCID: https://orcid.org/0000-0002-6462-8417)
- Biao Cai (ORCID: https://orcid.org/0000-0001-5046-9614)
- Guangwu Guo (ORCID: https://orcid.org/0009-0008-7594-124X)
Institutions
- Fujian Medical University (CN)
- Hubei University of Science and Technology (CN)
- Affiliated Hospital of Taishan Medical University (CN)
- Shandong First Medical University (CN)
- Union Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3389/fmed.2025.1687242
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- National Key Clinical Specialty Discipline Construction Program of China